- Home
- CNTA
as 05-30-2025 4:00pm EST
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
| Founded: | 2020 | Country: | United Kingdom |
| Employees: | N/A | City: | ALTRINCHAM, CHESHIRE |
| Market Cap: | 1.6B | IPO Year: | 2021 |
| Target Price: | $27.00 | AVG Volume (30 days): | 730.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.90 - $19.09 | Next Earning Date: | 05-14-2025 |
| Revenue: | $15,000,000 | Revenue Growth: | 118.88% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Centessa Pharmaceuticals plc (CNTA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| HUSSAIN IQBAL J | CNTA | General Counsel | May 1 '25 | Sell | $14.00 | 311 | $4,354.00 | 105,386 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | Apr 25 '25 | Sell | $14.00 | 5,689 | $79,658.01 | 105,386 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Apr 25 '25 | Sell | $13.61 | 11,742 | $159,856.76 | 122,279 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Apr 21 '25 | Sell | $12.36 | 55,000 | $681,576.18 | 221,017 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Mar 25 '25 | Sell | $16.34 | 10,000 | $163,386.00 | 122,279 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Mar 20 '25 | Sell | $16.69 | 55,000 | $918,060.00 | 221,017 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | Mar 17 '25 | Sell | $16.45 | 6,000 | $98,697.00 | 105,386 | |
| CHAO DAVID M | CNTA | Chief Administrative Officer | Mar 17 '25 | Sell | $17.29 | 7,000 | $120,205.87 | 226,529 |
Latest Centessa Pharmaceuticals plc News
CNTA Breaking Stock News: Dive into CNTA Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Needham Initiates Centessa Pharmaceuticals ADR at Buy With $35 Price Target
MT Newswires
11 days ago
Centessa Pharmaceuticals Insider Sold Shares Worth $699,111, According to a Recent SEC Filing
GlobeNewswire
13 days ago
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
MT Newswires
18 days ago
Centessa Pharmaceuticals Posts Revenue, Q1 Net Loss Narrows
GlobeNewswire
18 days ago
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
TipRanks
22 days ago
Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz
MT Newswires
24 days ago
Chardan Initiates Centessa Pharmaceuticals at Buy With $30 Price Target
Insider Monkey
a month ago
Is Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
Compare CNTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTA Centessa Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.